COHANCE.NS Cash Flow
Cohance Lifesciences Ltd.
Profit & Loss Balance Sheet Cash Flow
Cash Flow · 4 years on file
(FY2022-23 to FY2025-26)
· fetched 2026-08-23 21:43
| Line item | FY2022-23 | FY2023-24 | FY2024-25 | FY2025-26 | Source (XBRL element) |
|---|---|---|---|---|---|
| Net Cash from Operating Activities | ₹4.51 Bn | ₹3.58 Bn | ₹2.88 Bn | ₹3.68 Bn | CashFlowsFromUsedInOperatingActivities |
| Net Cash from Investing Activities | ₹-1.95 Bn | ₹-3.62 Bn | ₹-2.55 Bn | ₹-2.55 Bn | CashFlowsFromUsedInInvestingActivities |
| Net Cash from Financing Activities | ₹-2.36 Bn | ₹-0.14 Bn | ₹0.03 Bn | ₹-1.65 Bn | CashFlowsFromUsedInFinancingActivities |
| Effect of Exchange Rate Changes | ₹0.00 Bn | ₹0.00 Bn | ₹0.02 Bn | ₹0.04 Bn | EffectOfExchangeRateChangesOnCashAndCashEquivalents |
| Net Increase/(Decrease) in Cash | ₹0.20 Bn | ₹-0.18 Bn | ₹0.38 Bn | ₹-0.48 Bn | IncreaseDecreaseInCashAndCashEquivalents |
| Cash and Cash Equivalents (Closing) | ₹0.45 Bn | ₹0.65 Bn | N/A | N/A | CashAndCashEquivalentsCashFlowStatement |
Every figure above is the exact value of the named XBRL element from COHANCE.NS's cached filing for that year — nothing here is estimated or backfilled. A company shows one column per year StockProof actually has data for — never padded with blank years. Rows shown as N/A are genuinely not disclosed under that year's filing format (see peer comparison for how other Healthcare companies compare).